Mechanistically, talazoparib inhibits tumour cell growth through promoting lncRNA PLK4 up‐regulation specifically, followed by YAP inactivation, ultimately leading to cellular senescence of hepatoma cells. This evidence concerns the gene PLK4 and neoplasm.